{'fraction_non_alphanumeric': 0.038869257950530034, 'fraction_numerical': 0.02237926972909305, 'mean_word_length': 5.343283582089552, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prediction of steady‐state imipramine and desmethylimipramine plasma concentrations from single‐dose data

Tricyclic antidepressant plasma levels were measured in patients and healthy subjects after a single dose of desmethylimipramine (DM1) or imipramine (IMl) and after chronic dosing to steady states. Tricyclic plasma levels measured 24 hr after the single oral dose correlated with steady‐state plasma levels. In patients receiving DM1 there was a correlation (r = 0.97, n = 10) between 24‐hr and steady‐state DM1 levels, while in normal subjects receiving IMI the correlation was r = 0.92 (n = 20) between 24‐hr and steady‐state total tricyclic levels (IMI plus its metabolite, DMI). These results suggest the possibility that after a test dose of tricyclic antidepressant, a patient may be put on a “therapeutic” dosage regimen without delay.